| Literature DB >> 30469402 |
Ji Hye Kim1,2, Jae-Eun Lee3, Kyoung Heon Kim4, Nam Joo Kang5.
Abstract
Marine algae are considered to be an abundant sources of bioactive compounds with cosmeceutical potential. Recently, a great deal of interest has focused on the health-promoting effects of marine bioactive compounds. Carbohydrates are the major and abundant constituent of marine algae and have been utilized in cosmetic formulations, as moisturizing and thickening agents for example. In addition, marine carbohydrates have been suggested as promising bioactive biomaterials for their various properties beneficial to skin, including antioxidant, anti-melanogenic and skin anti-aging properties. Therefore, marine algae carbohydrates have potential skin health benefits for value-added cosmeceutical applications. The present review focuses on the various biological capacities and potential skin health benefits of bioactive marine carbohydrates.Entities:
Keywords: carbohydrates; cosmeceuticals; marine algae; monosaccharides; oligosaccharides; skin health
Mesh:
Substances:
Year: 2018 PMID: 30469402 PMCID: PMC6266229 DOI: 10.3390/md16110459
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Bioactive functions of marine algal extracts.
| Species | Solvent | Function | Mechanism | Ref. |
|---|---|---|---|---|
|
| A | Anti-melanogenesis | In vitro (B16F10 cells) | [ |
|
| In vivo (Zebrafish) | |||
|
| A | Anti-melanogenesis | In vitro (B16F10 cells) | [ |
|
| E, H | Anti-melanogenesis | In vitro (HEMs) | [ |
|
| A | Anti-melanogenesis | In vitro (B16F10 cells) | [ |
|
| M, C, | Antioxidant | In vitro | [ |
|
| ||||
|
| ||||
| A | Skin anti-aging | In vivo (human cheek skin) | [ | |
|
| PBS w/o Mg and Ca (pH 7) | Skin anti-aging | In vitro (HEKs, HDFs) | [ |
| In vivo (Human skin) | ||||
|
| A | Antioxidant | In vitro (NIH3T3 cells) | [ |
| Skin anti-aging | In vitro (HaCaT cells) | |||
| Anti-inflammation | In vitro (RAW 264.7 cells) | |||
|
| A | Anti-atopic dermatitis | In vivo (NC/Nga mice) | [ |
| Spring water | Anti-skin inflammation | In vivo (hairless Skh-1 mice) | [ | |
|
| Anti-skin cancer | In vivo | [ | |
| Spring water | Anti-skin inflammation | In vivo (hairless Skh-1 mice) | [ | |
| M | UV protection | In vitro (HaCaT cells) | [ | |
| A | UV protection | In vivo (HRS⁄ J-hairless mice) | [ | |
|
| A | Skin anti-aging | In vitro (HDFs) | [ |
| Skin anti-aging | In vivo (Human skin) | [ |
A: aqueous extract, AD: atopic dermatitis, AQP3: aquaporin-3, C: chloroform extract, Ca: calcium, DFE: Dermatophagoides farinae extract, DMBA: 7,12-dimethylbenz [a] anthracene, DPPH: 2,2-diphenyl-1-picrylhydrazyl, E: ethanol extract, EAc: ethyl acetate extract, ERK: extracellular signal–regulated kinase, FLG: filaggrin, H: hexane extract, HaCaT cells: immortalized human keratinocytes, HDFs: human dermal fibroblasts, HEKs: human epidermal keratinocytes, HEMs: human epidermal melanocytes, IFN-γ: interferon-gamma, IL-4: interleukin-4, iNOS: inducible nitric oxide synthase, INV: involucrin, JNK: c-Jun N-terminal kinase, LOR: loricrin, M: methanol extract, MDC: macrophage-derived chemokine, Mg: magnesium, MMP-1: matrix metalloproteinase-1, NIH3T3 cells: mouse embryo fibroblast cells, NO: nitric oxide, ORAC: oxygen radical absorbance capacity, PBS: phosphate-buffered saline, TARC: thymus- and activation-regulated chemokine, TEWL: transepidermal water loss, TGM-1: transglutaminase-1, TPA: 12-O-tetradecanoylphorbol-13-acetate, TYR: tyrosinase, UVA: ultraviolet A, UVB: ultraviolet B, w/o: without.
Bioactive functions of marine algal polysaccharides.
| Species | Saccharides | Function | Mechanism | Ref. |
|---|---|---|---|---|
| Fucoidan | Anti-melanogenesis | In vitro (Mel-Ab cells) | [ | |
|
| Fucoidan | Antioxidant | In vitro | [ |
|
| Fucoidan | Skin anti-aging | In vitro (HS68 cells) | [ |
| Fucoidan | In vitro (HaCaT cells) | [ | ||
|
| Fucoidan | In vivo | [ | |
|
| Fucoidan (16 kDa) by acidic hydrolysis | In vitro (HDFs) | [ | |
|
| Fucoidan | Anti-atopic dermatitis | In vivo (Nc/Nga mice) | [ |
| in vitro | ||||
| Fucoidan | [ | |||
|
| Fucoidan | Moisturizing | Higher moisture-absorption and moisture-retention ability than HA | [ |
|
| Fucoidan | Anti-skin cancer | In vitro (JB6 Cl41 cells) | [ |
|
| Laminaran | Skin anti-aging | In vivo (Kunming SPF mice) | [ |
| Dermal tissue-engineered production | Deposition of matrix (↑) | [ | ||
|
| Ulvans | Antioxidant | In vitro | [ |
| Acetylated and | [ | |||
| Crude ulvans (57 kDa) | Skin anti-aging | In vitro (HDFs) | [ | |
| Porphyran | Antioxidant | In vitro | [ | |
|
| Porphyran | In vivo (Kumming mice) | [ | |
| Porphyran with | In vitro | [ | ||
| LMW Porphyran | In vitro | [ | ||
|
| Porphyran | Anti-inflammation | In vitro (RAW264.7 cells) | [ |
|
| Carrageenan | Anti-melanogenesis | In vivo (Guinea pig) | [ |
|
| Antioxidant | In vitro (HaCaT cells) | [ | |
|
| ||||
|
| ||||
| κ-COSs | Antioxidant | In vitro | [ | |
| κ-COSs | In vitro | [ | ||
| κ-COSs with CP | Photo-protective | In vitro (HaCaT cells, MEFs) | [ |
AD: atopic dermatitis, BD: benzoylated derivatives, COSs: carrageenan oligosaccharides, CP: collagen peptide, DCF-DA: 2′,7′-dichlorofluorescin diacetate, DNCB: 2,4-dinitrochlorobenzene, DPPH: 2,2-diphenyl-1-picrylhydrazyl, EGF: epidermal growth factor, EGFR: epidermal growth factor receptor, ERK: extracellular signal–regulated kinase, FRAP: ferric reducing antioxidant power, GSH-Px: glutathione peroxidase, HA: hyaluronic acid, HaCaT cells: immortalized human keratinocytes, HDFs: human dermal fibroblasts, HS68 cells: human foreskin fibroblast, Hyp: hydroxyproline, IgE: immunoglobulin E, IκB-α: inhibitor of kappa B, IL-1β: interleukin-1β, IFN-γ: interferon-gamma, iNOS: inducible nitric oxide synthase, iota 2 [ι(ІІ)],iota 5 [ι (V)],JB6 cells: mouse epidermal cells, JNK: c-Jun N-terminal kinase, kappa (κ),lambda (λ)kappa [κ(ІІІ)],LMW: low molecular weight, LPS: lipopolysaccharide, MDA: malondialdehyde, MDC: macrophage-derived chemokine, MEF: mouse embryonic fibroblasts, Mel-Ab cells: immortalized murine melanocyte cell line, MMP-1: matrix metalloproteinase-1, MMP-3: matrix metalloproteinase-3, MMP-9: matrix metalloproteinase-9, MW: molecular weight, NF-κB: nuclear factor kappa B, NO: nitric oxide, PBMC: peripheral blood mononuclear cell, PD: phosphorylated derivatives, RANTES: regulated upon activation, normal T-cell expressed and secreted chemokine, ROS: reactive oxygen species, SD: sulfated derivatives, SOD: superoxide dismutase, SPF: specific pathogen free, TAOC: total antioxidant capacity, TARC: thymus- and activation-regulated chemokine, TIMP-1: tissue inhibitor of metalloproteinases inhibitor 1, TNF: tumor necrosis factor, TPA: 12-O-tetradecanoylphorbol-13-acetate, UVA: ultraviolet A, UVB: ultraviolet B.
Bioactive functions of marine algal monosaccharides and oligosaccharides.
| DP | Name | Mode of Linkage | Function | Mechanism | Ref. |
|---|---|---|---|---|---|
| 1 | D-Glucose | - | Anti-melanogenesis | In vitro (B16 cells) | [ |
| L-AHG | - | In vitro | [ | ||
| D-AHG | - | Anti-inflammation | In vitro (Raw264.7 cells) | [ | |
| D-Galactose |
| Melanogenesis | In vitro (B16 cells) | [ | |
| 2 | Agarobiose | Galβ1→4AHG | Antioxidant | In vitro | [ |
| Anti-inflammation | In vitro (RAW264.7 cell) | [ | |||
| In vitro (Human Monocytes) | |||||
| In vitro (Human Monocytes) | [ | ||||
| Neoagarobiose | AHGα1→3Gal | Anti-melanogenesis | In vitro (B16 cells) | [ | |
| Moisturizing | Higher moisture-absorption and moisture-retention ability than HA | ||||
| 3 | Agarotriose | Galβ1→4AHGα1→3Gal | N.a. | - | - |
| Neoagarotriose | AHGα1→3Galβ1→4AHG | N.a. | - | - | |
| 4 | Agarotetraose | Galβ1→4AHGα1→3Galβ1→4AHG | Antioxidant | In vitro | [ |
| Anti-inflammation | In vitro (RAW264.7 cell) | [ | |||
| Neoagarotetraose | AHGα1→3Galβ1→4AHGα1→3Gal | Anti-melanogenesis | In vitro (B16 cells or HEMs) | [ | |
| 5 | Agaropentaose | Galβ1→4AHGα1→3Galβ1→4AHGα1→3Gal | N.a. | - | - |
| Neoagaropentaose | AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHG | N.a. | - | - | |
| 6 | Agarohexaose | Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHG | Antioxidant | In vitro | [ |
| Anti-inflammation | In vitro (RAW264.7 cell) | [ | |||
| In vitro | [ | ||||
| Neoagarohexaose | AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Gal | Anti-melanogenesis | In vitro (B16 cells or HEMs) | [ | |
| 7 | Agaroheptaose | Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Gal | N.a. | - | - |
| Neoagaroheptaose | AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHG | N.a. | - | - | |
| 8 | Agarooctaose | Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHG | Antioxidant | In vitro | [ |
| Neoagarooctaose | AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Gal | N.a. | - | - | |
| 9 | Agarononaose | Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Gal | N.a. | - | - |
| Neoagarononaose | AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHG | N.a. | - | - | |
| 10 | Agarodecaose | Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHG | Antioxidant | In vitro | [ |
| Neoagarodecaose | AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Galβ1→4AHGα1→3Gal | N.a. | - | - | |
| - | Mixture of | [Galβ1→4AHG]n | Anti-melanogenesis | In vitro (B16 cells) | [ |
| Anti-skin cancer | In vivo (ICR mice) | [ | |||
| Anti-inflammation | In vitro (Human monocytes) |
AOSs: agaro-oligosaccharides, B16(F10) cells: mouse melanoma B16(F10) cells, COX-2: cyclooxygenase-2, D-AHG: 3,6-anhydro-D-galactose, DMBA: 12-dimethylbenz [a] anthracene, DP: degree of polymerization, DPPH: 2,2-diphenyl-1-picrylhydrazyl, HA: hyaluronan, HEMs: human epidermal melanocytes, HO-1: heme oxygenase-1, IL: interleukin, iNOS: Iiducible nitric oxide synthase, L-AHG: 3,6-anhydro-L-galactose, LPS: lipopolysaccharides, mPGES-1: microsomal prostaglandin E synthase-1, N.a.: not applicable, NO: nitric oxide, PGE2: prostaglandin E2, TNF: tumor necrosis factor, TPA: 12-O-tetradecanoylphorbol-13-acetate, TYR: tyrosinase, (-): not effective.